Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 11 of 11 for “"pulmonary exacerbations"”.

  1. Understanding and predicting pulmonary exacerbations in Cystic Fibrosis using Machine Learning

    … in respiratory symptoms - termed acute pulmonary exacerbations (APEs) - cause cumulative damage to the lungs, and are the most significant driver of mortality and morbidity in CF. However, despite this, currently little is known about their pathophysiology, nor what triggers them. The …

    cambridge Repository record for Understanding and predicting pulmonary exacerbations in Cystic Fibrosis using Machine Learning (opens in a new tab)

  2. Understanding and predicting acute pulmonary exacerbations in adults with cystic fibrosis

    ABSTRACT Understanding and predicting acute pulmonary exacerbations in adults with cystic fibrosis Dr Emem-Fong Ukor Cystic fibrosis (CF) is the most common, inherited, life-limiting, multi-system disorder among the Caucasian population. Disease arises from mutations in the cystic fibrosis …

    cambridge Repository record for Understanding and predicting acute pulmonary exacerbations in adults with cystic fibrosis (opens in a new tab)

  3. Longitudinal assessment of cystic fibrosis pulmonary diseaseusing clinical, biochemical and emerging microbiological techniques

    … infection leading to morbidity and mortality. CF Pulmonary Exacerbations (CFPEs) cause accentuated symptoms and increase mortality. The definition and aetiology of CFPEs has however proved elusive. Recently, culture independent techniques have shown that there is much greater diversity of bacteria …

    soton Repository record for Longitudinal assessment of cystic fibrosis pulmonary diseaseusing clinical, biochemical and emerging microbiological techniques (opens in a new tab)

  4. Cystic fibrosis and the gut microbiota

    … improvements in lung function and reductions in pulmonary exacerbations, the effects on the gut microbiota composition, function and metabolome were subtle. Pancreatic function was not restored and intestinal inflammation was not reduced following commencement of Ivacaftor treatment. Finally, in …

    cork Repository record for Cystic fibrosis and the gut microbiota (opens in a new tab)

  5. The Microbiome of Cystic Fibrosis Sputum and its Association with Incident Lower Airway Infections

    … pathogen of interest, associated with increased pulmonary exacerbations and lung function decline. This thesis aimed to explore the CF sputum microbiome of persons with CF (pwCF) uninfected with these pathogens and to determine if the risk of future acquisition and persistence of these pathogens …

    calgary Repository record for The Microbiome of Cystic Fibrosis Sputum and its Association with Incident Lower Airway Infections (opens in a new tab)

  6. A cystic fibrosis infection monitor

    … infections are almost impossible to eradicate. Pulmonary exacerbations, thought to be caused by P. aeruginosa, result in further damage that leads to deterioration in lung performance. A sensor that would allow rapid, near patient testing of sputum samples would be a valuable addition to CF care …

    strathclyde Repository record for A cystic fibrosis infection monitor (opens in a new tab)

  7. The genetics and phenotypes of Pseudomonas aeruginosa biofilm dispersal populations

    … aeruginosa in the lungs, resulting in chronic pulmonary exacerbations. The ability to colonize CF patients’ lungs and other environmental habitats has been attributed to the large genome size of P. aeruginosa, and its ability to form biofilms. The typical biofilm life cycle culminates in …

    unsw Repository record for The genetics and phenotypes of Pseudomonas aeruginosa biofilm dispersal populations (opens in a new tab)

  8. Burden of Illness and Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in Cystic Fibrosis

    … volume (FEV<sub>1</sub>% predicted)and pulmonary exacerbation values from TRAFFIC and TRANSPORT clinical trials and cost to treat pulmonary exacerbations from published literature. The outcomes in the CEA included total cost of therapy, average cost effectiveness ratio (ACER) defined as …

    duquesne Repository record for Burden of Illness and Pharmacoeconomic Evaluation of Lumacaftor/Ivacaftor in Cystic Fibrosis (opens in a new tab)

  9. Pseudomonas aeruginosa​ genetics and virulence in cystic fibrosis and bacteraemia

    … and rapid lung function decline, called acute pulmonary exacerbations (APEs). These isolates were previously analysed for the presence and absence of ten virulence-related phenotypes. The ​P. aeruginosa isolates were whole-genome sequenced to investigate the inter- and intra-patient genotypic …

    cambridge Repository record for Pseudomonas aeruginosa​ genetics and virulence in cystic fibrosis and bacteraemia (opens in a new tab)

  10. The effect of long-term azithromycin treatment on the respiratory microbiota of HIV-infected children with chronic lung disease

    … reduced the frequency of acute respiratory exacerbations and all-cause hospitalisations in HCLD patients. However, our understanding of the microbial determinants of HCLD and how azithromycin therapy modulates these determinants is limited. This study investigated the carriage and antibiotic …

    cape-town Repository record for The effect of long-term azithromycin treatment on the respiratory microbiota of HIV-infected children with chronic lung disease (opens in a new tab)